Literature DB >> 22959114

Onset, time course and trajectories of improvement with antidepressants.

Raymond W Lam1.   

Abstract

There is still considerable controversy about the onset and time course of improvement with antidepressants in the treatment of major depressive disorder. Previous studies suggested a delayed-onset hypothesis with therapeutic improvement taking several weeks, but recent meta-analyses have shown support for earlier onset of improvement within the first week or two of treatment. This paper briefly reviews the evidence, focused on antidepressant studies published since 2006, for early onset of improvement within the first 2 weeks of treatment. A PubMed electronic search was conducted with selection of relevant studies from 2007 to March 2012. With the caveat of methodological limitations, results from randomized clinical trials, meta-analyses and naturalistic studies consistently show that: (1) antidepressants in general have early onset of improvement, (2) some antidepressants, including the novel mechanism agent, agomelatine, are associated with early improvement in both core and specific symptoms such as anhedonia and sleep-wake disturbances, and (3) early improvement predicts sustained response and remission. Use of newer statistical methods to examine individual response trajectories may address some of the methodological limitations of previous studies. The predictive value of early improvement has important clinical relevance for antidepressant treatment. Measurement-based assessment for response should occur earlier and more frequently. A lack of improvement (defined as ≤20% reduction from baseline in scores on a depression rating scale) at 2-3 weeks after initiation of an antidepressant should prompt the clinician to consider a change in management.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959114     DOI: 10.1016/j.euroneuro.2012.07.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  17 in total

1.  Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons.

Authors:  Daniel J Urban; Hu Zhu; Catherine A Marcinkiewcz; Michael Michaelides; Hidehiro Oshibuchi; Darren Rhea; Dipendra K Aryal; Martilias S Farrell; Emily Lowery-Gionta; Reid H J Olsen; William C Wetsel; Thomas L Kash; Yasmin L Hurd; Laurence H Tecott; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2015-09-18       Impact factor: 7.853

2.  Repeated transcranial direct current stimulation prevents abnormal behaviors associated with abstinence from chronic nicotine consumption.

Authors:  Solène Pedron; Julie Monnin; Emmanuel Haffen; Daniel Sechter; Vincent Van Waes
Journal:  Neuropsychopharmacology       Date:  2013-10-24       Impact factor: 7.853

3.  When should governments increase the supply of psychiatric beds?

Authors:  S Allison; T Bastiampillai; J Licinio; D A Fuller; N Bidargaddi; S S Sharfstein
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

4.  Upregulation of antioxidant thioredoxin by antidepressants fluoxetine and venlafaxine.

Authors:  Veni Bharti; Hua Tan; Jaspreet Deol; Zijian Wu; Jun-Feng Wang
Journal:  Psychopharmacology (Berl)       Date:  2019-08-31       Impact factor: 4.530

5.  A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety.

Authors:  William Vaughn McCall; Ruth M Benca; Peter B Rosenquist; Mary Anne Riley; Chelsea Hodges; Brittany Gubosh; Laryssa McCloud; Jill C Newman; Doug Case; Meredith Rumble; Mark Mayo; Kaitlin Hanley White; Marjorie Phillips; Andrew D Krystal
Journal:  Clin Trials       Date:  2015-03-01       Impact factor: 2.486

Review 6.  Adult neurogenesis and mental illness.

Authors:  Timothy J Schoenfeld; Heather A Cameron
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

7.  Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.

Authors:  Zane Zeier; Linda L Carpenter; Ned H Kalin; Carolyn I Rodriguez; William M McDonald; Alik S Widge; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2018-04-25       Impact factor: 18.112

Review 8.  Early switching strategies in antidepressant non-responders: current evidence and future research directions.

Authors:  Paul A Kudlow; Roger S McIntyre; Raymond W Lam
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

9.  Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings.

Authors:  Arjun P Athreya; Tanja Brückl; Elisabeth B Binder; A John Rush; Joanna Biernacka; Mark A Frye; Drew Neavin; Michelle Skime; Ditlev Monrad; Ravishankar K Iyer; Taryn Mayes; Madhukar Trivedi; Rickey E Carter; Liewei Wang; Richard M Weinshilboum; Paul E Croarkin; William V Bobo
Journal:  Neuropsychopharmacology       Date:  2021-01-15       Impact factor: 7.853

10.  Pregnanolone Glutamate, a Novel Use-Dependent NMDA Receptor Inhibitor, Exerts Antidepressant-Like Properties in Animal Models.

Authors:  Kristina Holubova; Tereza Nekovarova; Jana Pistovcakova; Alexandra Sulcova; Ales Stuchlík; Karel Vales
Journal:  Front Behav Neurosci       Date:  2014-04-16       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.